GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » EV-to-EBIT

Amoy Diagnostics Co (SZSE:300685) EV-to-EBIT : 21.23 (As of May. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amoy Diagnostics Co's Enterprise Value is ¥6,459 Mil. Amoy Diagnostics Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥304 Mil. Therefore, Amoy Diagnostics Co's EV-to-EBIT for today is 21.23.

The historical rank and industry rank for Amoy Diagnostics Co's EV-to-EBIT or its related term are showing as below:

SZSE:300685' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5   Med: 45.12   Max: 161.01
Current: 21.23

During the past 12 years, the highest EV-to-EBIT of Amoy Diagnostics Co was 161.01. The lowest was 7.50. And the median was 45.12.

SZSE:300685's EV-to-EBIT is ranked better than
52.88% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 22.755 vs SZSE:300685: 21.23

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Amoy Diagnostics Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥7,683 Mil. Amoy Diagnostics Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥304 Mil. Amoy Diagnostics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3.96%.


Amoy Diagnostics Co EV-to-EBIT Historical Data

The historical data trend for Amoy Diagnostics Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co EV-to-EBIT Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.70 82.82 63.54 34.24 26.33

Amoy Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.64 27.33 40.33 26.33 25.25

Competitive Comparison of Amoy Diagnostics Co's EV-to-EBIT

For the Diagnostics & Research subindustry, Amoy Diagnostics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amoy Diagnostics Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Amoy Diagnostics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Amoy Diagnostics Co's EV-to-EBIT falls into.



Amoy Diagnostics Co EV-to-EBIT Calculation

Amoy Diagnostics Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6458.995/304.226
=21.23

Amoy Diagnostics Co's current Enterprise Value is ¥6,459 Mil.
Amoy Diagnostics Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥304 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amoy Diagnostics Co  (SZSE:300685) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Amoy Diagnostics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=304.226/7682.5078
=3.96 %

Amoy Diagnostics Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥7,683 Mil.
Amoy Diagnostics Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥304 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amoy Diagnostics Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Amoy Diagnostics Co (SZSE:300685) Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines